Patient Acceptance of Semi-Inpatient Radioligand Therapy: Insights from a Prospective Survey in Nuclear Medicine
Nuklearmedizin - NuclearMedicine · 26.10.2026
DOI: 10.1055/a-2966-9616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 26.10.2026. Verfasst von Jonas Kaufmann und 15 weiteren Autor:innen. Beteiligte Einrichtung: Charité University Hospital Berlin, Department of Anesthesiology and Operative Intensive Care Medicine, BE, Germany, Berlin. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radioligand therapy with lutetium-177 is an effective treatment option for patients with metastatic castration-resistant prostate cancer and metastatic neuroendocrine tumors. In Germany, radiation protection laws require hospitalization with isolation, which may cause capacity problems. Internationally, models show the feasibility of non-inpatient radioligand therapy under strict safety measures. Patient acceptance is crucial for the implementation of flexible care models. This study aimed to assess patient preferences, concerns and requirements for non-inpatient radioligand therapy. An anonymous cross-sectional study was conducted in 46 patients receiving radioligand therapy in a nuclear medicine department. The questionnaire collected demographic and clinical data, treatment preferences, benefits and limitations of various care settings and factors influencing the acceptance of outpatient treatments. Analysis was done descriptively. Most patients (95.7%) valued inpatient monitoring and safety. However, 53.2% of patients preferred a shortened hospital stay and 54.4% of patients rated semi-inpatient care as ideal. Only 8.9% of patients supported a fully outpatient approach. Key barriers to home-based care are radiation exposure and lack of medical supervision. Patients with better performance status showed greater acceptance to non-inpatient models. Educational materials and guaranteed telephone access to clinical staff were identified as important for increasing acceptance. Patients express a strong interest in individualized, flexible radioligand therapy with reliable safety structures. Risk-adapted semi-inpatient models may improve patient-centered care and alleviate pressure on inpatient resources. However, potential risks as radiation exposure to family members and subsequent safety measures need to be explored in controlled trials.
Autor:innen und Institutionen
- Charité University Hospital Berlin, Department of Anesthesiology and Operative Intensive Care Medicine, BE, Germany, Berlin.
- Charité University Hospital Berlin, Department of Nuclear Medicine, BE, Germany, Berlin.
- Charité University Hospital Berlin, Radiation Protection Department, BE, Germany, Berlin.
- Charité University Hospital Berlin, Institute of Health and Nursing Science, BE, Germany, Berlin.
ORCID-Profile: Jonas Kaufmann
Zitieren
APA
Kaufmann, J., Kattinger, C., Blümel, S., Bartel, C., Glaß, M. H., Dahlke, P. M., Thormann, M., Ströhl, Y., Herden, A., Ruhwedel, T., Metzger, G., Galler, M., Rogasch, J. M. M., Amthauer, H., Ewers, M., & Furth, C. (2026). Patient Acceptance of Semi-Inpatient Radioligand Therapy: Insights from a Prospective Survey in Nuclear Medicine. Nuklearmedizin - NuclearMedicine. https://doi.org/10.1055/a-2966-9616
Vancouver
Kaufmann J, Kattinger C, Blümel S, Bartel C, Glaß MH, Dahlke PM, et al. Patient Acceptance of Semi-Inpatient Radioligand Therapy: Insights from a Prospective Survey in Nuclear Medicine. Nuklearmedizin - NuclearMedicine. 2026. doi:10.1055/a-2966-9616
BibTeX
@article{Kaufmann2026,
author = {Kaufmann, Jonas and Kattinger, Carsten and Blümel, Stephanie and Bartel, Christina and Glaß, Mia Hami and Dahlke, Paul Martin and Thormann, Maximilian and Ströhl, Yasmin and Herden, Anna and Ruhwedel, Tristan and Metzger, Giulia and Galler, Markus and Rogasch, Julian Manuel Michael and Amthauer, Holger and Ewers, Michael and Furth, Christian},
title = {Patient Acceptance of Semi-Inpatient Radioligand Therapy: Insights from a Prospective Survey in Nuclear Medicine},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2026},
doi = {10.1055/a-2966-9616}
}
EUVIMED